Effects of huperzine A on acetylcholinesterase isoforms in vitro: Comparison with tacrine, donepezil, rivastigmine and physostigmine

European Journal of Pharmacology

Volumn 455, Issue 2-3, 2002, Pages 101-107

  Zhao, Qin ^a   Tang, Xi Can ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

(Rat); Acetylcholinesterase isoform; Alzheimer's disease; Donepezil; Huperzine A; Physostigmine; Rivastigmine; Tacrine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; HUPERZINE A; ISOENZYME; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; CARBAMIC ACID DERIVATIVE; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE; SESQUITERPENE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; COMPARATIVE STUDY; ENZYMOLOGY; KINETICS; METABOLISM; SPRAGUE DAWLEY RAT;

ACETYLCHOLINESTERASE; ANIMALS; CARBAMATES; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; CORPUS STRIATUM; HIPPOCAMPUS; INDANS; ISOENZYMES; KINETICS; MALE; PHENYLCARBAMATES; PHYSOSTIGMINE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; TACRINE;

EID: 0037195557     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02589-X     Document Type: Article

References (33)

1. Ariel N., Ordentlich A., Barak D., Bino T., Velan B., Shafferman A. The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active center allows for versatile interaction modes with inhibitors. Biochem. J. 335(Pt 1):1998;95-102.
2. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-414.
3. Bon S., Vigny M., Massoulie J. Asymmetric and globular forms of AChE in mammals and birds. Proc. Natl. Acad. Sci. U. S. A. 76:1979;2540-2550.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
5. Brimijoin S. Molecular forms of acetylcholinesterase in brain, nerve and muscle: nature, localization and dynamics. Prog. Neurobiol. 21:1983;291-322.
6. Candy J.W., Perry R.H., Perry E.K., Irving D., Blessed G., Fairbairn A.F. Pathological changes in the nucleus basalis of Meynert in Alzheimer's and Parkinson's disease. J. Neurol. Sci. 59:1983;277-289.
7. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
8. Coyle J.T., Price D.L., Delong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190.
9. Das A.M., Dikshit C.N. Profile of acetylcholinesterase in brain areas of male and female rats of adult and old age. Life Sci. 68:2001;1545-1555.
10. Dekosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27:1990;457-464.
11. Ellman G.L., Courtney K.D., Andres V. Jr., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
12. Giacobini E. Cholinesterase inhibitors: from the calabar bean to Alzheimer therapy. Giacobini E. Cholinesterases and Cholinesterase Inhibitors. 2000;181-226 Martin Dunitz, Thonex-Geneva.
13. Gottwald M.D., Rozanski R.I. Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin. Investig. Drugs. 10:1999;1673-1682.
14. Grassi J., Vigny M., Massoulie J. Molecular forms of acetylcholinesterase in bovine caudate nucleus and superior cervical ganglion: solubility properties and hydrophobic character. J. Neurochem. 387:1982;457-469.
15. Kawaguchi Y., Wilson C.J., Augood S.J., Emxon P.C. Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci. 18:1995;527-535.
16. Massoulie J., Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrate. Annu. Rev. Neurosci. 5:1982;57-106.
17. Ogane N., Giacobini E., Struble R. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. Brain Res. 589:1992;307-312.
18. Polinsky R.J. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Clin. Ther. 4:1998;634-647.
19. Radic Z., Taylor P. Interaction kinetics of reversible inhibitors and substrates with acetylcholinesterase and its fasciculin 2 complex. J. Biol. Chem. 16:2001;4622-4633.
20. Saez-Valero J., Tornet P.L., Munoz-Delgado E., Vidal C.J. Amphiphilic and hydrophilic forms of acetyl- and butyrylcholinesterase in human brain. J. Neurosci. Res. 35:1993;678-689.
21. Saxena A., Redman A.M., Jiang X., Lockridge O., Doctor B.P. Differences in active-site gorge dimensions of cholinesterase revealed by binding of inhibitors to human butyrylcholinesterase. Chem. Biol. Interact. 119-120:1999;61-69.
22. Serena A., Alessia L., Rita R., Cinzia A., Virgilio G., Lucilla P. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine. Mech. Ageing Dev. 122:2001;2057-2062.
23. Siek G.C., Katz L.S., Fishman E.B., Korosi T.S., Marquis J.K. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer's disease brain. Biol. Psychiatry. 6:1990;573-580.
24. Silman I., Sussman J.L. Structural studies on acetylcholinesterase. Giacobini E. Cholinesterases and Cholinesterase Inhibitors. 2000;9-25 Martin Dunitz, Thonex-Geneva.
25. Skau K.A., Shipley M.T. Phenylmethylsulfonyl fluoride inhibitory effects in acetylcholinesterase of brain and muscle. Neuropharmacology. 38:1999;691-698.
26. Tang X.C., He X.C., Bai D.L. Huperzine A: a novel acetylcholinesterase inhibitor. Drugs Future. 24:1999;67-663.
27. Taylor P., Radic Z. The cholinesterases: from genes to proteins. Annu. Rev. Pharmacol. Toxicol. 34:1994;281-320.
28. Taylor P., Rieger F., Shelanski M., Greene L. Cellular localization of the multiple molecular forms of acetylcholinesterase in cultured neuronal cells. J. Biol. Chem. 256:1981;3827-3830.
29. Taylor P., Schumacher M., Maulet Y., Newton M. A molecular perspective on the polymorphism of acetylcholinesterase. Trends Pharmacol. Sci. 8:1986;321-323.
30. Terry R.D., Masliah E. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30:1991;572-580.
31. Vigny M., Bon S., Massoulie J., Leterrier F. Active site catalytic efficiency of acetylcholinesterase molecular forms in electrophorus, torpedo, rat and chicken. Eur. J. Biochem. 85:1978;317-323.
32. Xu S.S., Gao Z.X., Weng Z. Efficacy of tablet huperzine-A on memory, cognition and behavior in Alzheimer's disease. Acta Pharm. Sin. 16:1995;391-395.
33. Zhao Q., Tang X.C. Isolation of acetylcholinesterase G4 and G1 molecular isoforms from rat cortex. Acta Pharm. Sin. 2:2002;173-176.